期刊
MEDICAL CLINICS OF NORTH AMERICA
卷 99, 期 1, 页码 87-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.mcna.2014.08.012
关键词
Metformin; Sulfonylureas; Thiazolidinediones; Sodium-glucose transporter-2 inhibitors (SGLT2 inhibitors); Colesevelam; Bromocriptine; Type 2 diabetes mellitus
The epidemic of type 2 diabetes mellitus has been met by evolving strategy and clinical tactics, including the generally-accepted recommendation to initiate drug therapy concurrent with therapeutic lifestyle changes. Barring contraindications, metformin should be the first drug treatment prescribed, based on considerations of cost, efficacy, and safety. When metformin monotherapy fails to produce the goal for glycemic control, add-on therapy can include a sulfonylurea, a sodium-glucose transporter type 2 inhibitor, an alpha-glucosidase inhibitor, or a thiazolidinedione. New niche therapies include colesevelam and bromocriptine mesylate. Consideration should be given to the effect of the drug therapy on cardiovascular disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据